← Back to Clinical Trials
Recruiting NCT06955832

NCT06955832 Early Identification of Brain Lesions in Multiple Sclerosis With Phase Sensitive Inversion Recovery MRI

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06955832
Status Recruiting
Phase
Sponsor Benha University
Condition Multiple Sclerosis
Study Type OBSERVATIONAL
Enrollment 30 participants
Start Date 2025-06
Primary Completion 2025-06

Eligibility & Interventions

Sex All sexes
Min Age 15 Years
Max Age 65 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 30 participants in total. It began in 2025-06 with a primary completion date of 2025-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this observational study is to compare the diagnostic accuracy of Phase-Sensitive Inversion Recovery (PSIR) MRI versus conventional T2-weighted (T2W) and Fluid Attenuated Inversion Recovery (FLAIR) sequences in detecting early brain lesions in patients with Multiple Sclerosis (MS). The study will include male and female participants aged 15-65 years diagnosed with MS per the 2017 McDonald criteria. This study hypothesizes that: * PSIR MRI will detect a significantly higher number of cortical lesions (intracortical, leukocortical, and juxtacortical) compared to conventional T2W and FLAIR sequences in MS patients (p \< 0.05). * Lesions identified exclusively by PSIR will correlate more strongly with clinical measures (EDSS disability scores and SDMT cognitive performance) than those detected by T2W/FLAIR alone, suggesting PSIR's superior sensitivity to clinically relevant pathology.

Eligibility Criteria

Inclusion Criteria: * Age between 15-65 years. * Both sexes. * Patients with MS according to McDonald Criterion Exclusion Criteria: * Age less than 15 years old. * Patients with stroke or previous intracranial hemorrhage. * Contraindications to MRI scans. * MS mimics.

Frequently Asked Questions

Who can join the NCT06955832 clinical trial?

This trial is open to participants of all sexes, aged 15 Years or older, up to 65 Years, studying Multiple Sclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06955832 currently recruiting?

Yes, NCT06955832 is actively recruiting participants. Visit ClinicalTrials.gov or contact Benha University to inquire about joining.

Where is the NCT06955832 trial being conducted?

This trial is being conducted at Banhā, Egypt, Cairo, Egypt, Cairo, Egypt.

Who is sponsoring the NCT06955832 clinical trial?

NCT06955832 is sponsored by Benha University. The trial plans to enroll 30 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology